DR PALAK SAKARIA

DR. SAUMIL K. KOTHARI

Abstract

Objective: To evaluate Netarsudil’s role as a 5th line anti glaucoma medication (AGM) in patients with advanced glaucoma. To check real world clinical impact.

Methodology: Prospective study design from Nov.’20 to June’21 with at least 12 weeks follow up. Netarsudil 0.02% eye drops prescribed as a once night time dose in patients whose IOP is not on target or visual fields are showing progression, who are already on 4 AGM, who are not willing to undergo glaucoma filtering surgery or LASER treatment. IOP was monitored at 2nd, 4th, 12th week. Visual field tests were done at week 0 and 12.

Results: 20 eyes of 20 patients with a mean age of 65.5 (∓7.3) years were included. Mean IOP was 22.1(∓3.8) mm of Hg. IOP at week 2 was 19.55(∓3.9), week 4 19(∓3.6), week 12 19(∓3.6)mm of Hg. 5(25%) eyes did now show any change in IOP. 7(35%) eyes showed visual field progression. 8(40%) eyes had conj. hyperemia.

Conclusion: Netarsudil as a 5th line AGM showed a drop in mean IOP of 3.1 mm of Hg(14%).